[
    {
        "pregunta": "1. What are the recommended treatment options for glucocorticoid-induced osteoporosis in patients with very high fracture risk?",
        "respuesta": "For patients with glucocorticoid-induced osteoporosis (GIOP) who are at very high fracture risk due to treatment with one or more courses of high-dose glucocorticoid therapy (mean dose of prednisone equivalent ≥30 mg daily for ≥30 days) or a cumulative glucocorticoid dose ≥5 g over 1 year, the 2022 American College of Rheumatology guideline conditionally recommends treating with parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP) over anti-resorptive agents, regardless of FRAX score or bone mineral density (BMD). In addition, the guideline strongly recommends the use of oral bisphosphonates over no treatment and conditionally recommends intravenous bisphosphonates, denosumab, raloxifene, or romosozumab over no treatment.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      895E00BE431C5D109F968BA8D0506240 10.1002/acr.25240 Submitted for publication December 1, 2022; accepted in revised form July 3, 2023.  INTRODUCTION Glucocorticoids (GCs) remain a common therapeutic modality for patients with a variety of diseases. Prevention of GC-induced bone loss and fractures has been a focus of the American College of Rheumatology (ACR) for many",
            "at very high fracture risk due to treatment with one or more courses of high-dose GC therapy (mean dose prednisone equivalent ≥30 mg daily for ≥30 days) or cumulative GC dose ≥5 g over 1 year, we conditionally recommend treating with PTH/PTHrP over anti-resorptive agents regardless of FRAX score or BMD. We strongly recommend oral BP over no treatment and conditionally recommend an IV BP, DEN, RAL or ROM over no treatment. The relative risk for vertebral fracture was 14 and for hip fractures was",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day"
        ]
    },
    {
        "pregunta": "2. Why is it important to reassess fracture risk in patients continuing chronic glucocorticoid therapy?",
        "respuesta": "It is important to reassess fracture risk in patients who are continuing chronic glucocorticoid (GC) therapy because reassessment allows providers to determine if patients continuing GC and osteoporosis (OP) therapy are maintaining, gaining, or losing bone mineral density (BMD), warranting possible changes in OP therapy. For patients at very high fracture risk, yearly BMD assessment until a stable BMD is reached may be preferred. This is highlighted as good clinical practice despite the low certainty of the evidence. Regular reassessment, which includes clinical fracture risk history, new symptomatic fractures, and diagnostic measures like FRAX, BMD, vertebral fracture assessment (VFA), and/or spine x-rays, ensures that changes in treatment can be made proactively to help prevent further bone deterioration and fractures.",
        "contexto": [
            "or continuing GC therapy, despite the low certainty of the evidence. Initial assessment should occur as soon as possible within 6 months of GC therapy initiation. Clinical fracture risk assessment includes dose, duration, and pattern of GC use, alcohol use, smoking history, hypogonadism, history of prior fractures (traumatic, fragility, asymptomatic), low body weight, significant weight loss, parental history of hip fracture, fall history, thyroid disease, hyperparathyroidism, rheumatoid",
            "risk who chose not to start OP therapy (except calcium and vitamin D), we strongly recommend fracture risk reassessment every 1 to 2 years (PICO 9.1-9.4). Despite the low certainty of the evidence, this is a strong recommendation as good clinical practice. Fracture risk reassessment includes clinical fracture risk history, new symptomatic fractures, FRAX, BMD, VFA, and/or spine x-rays. Repeating DXA assessment every 1 to 2 years allows providers to detect the least significant BMD change",
            "of the evidence, this is a strong recommendation as good clinical practice. Reassessment allows providers to determine if patients continuing GC and OP therapy are maintaining, gaining, or losing BMD, warranting possible changes in OP therapy. Yearly BMD assessment until a stable BMD is reached may be preferred in very high fracture risk patients. For adults stopping GC and remaining at moderate, high, or very high fracture risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline"
        ]
    },
    {
        "pregunta": "3. Which medications are strongly recommended for adults with high fracture risk due to glucocorticoid therapy?",
        "respuesta": "For adults at high fracture risk due to long-term glucocorticoid therapy, the 2022 American College of Rheumatology guideline strongly recommends the use of oral bisphosphonates over no treatment. This recommendation is based on the available fracture data in glucocorticoid-induced osteoporosis populations.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "strongly recommend against adding oral or IV BP, PTH/PTHrP, RAL, DEN, or ROM (PICO 1.4a-1.28a). Adults <40 years have low fracture risk and have significant capacity to rebuild BMD losses induced by chronic GC therapy. OP therapy should not be started in this low-risk group Recommendations for special populations of patients beginning long-term GC therapy at very high risk for fracture (Table 2 For adults ≥40 years at very high fracture risk due to treatment with one or more courses of",
            "|For adults ≥40 years with low fracture risk, we strongly recommend against OP medications due to known risk of harms and no evidence of benefit.|Very low|4.4a–4.13a|91–101|\n|Adults receiving high-dose GC (initial dose≥30 mg/day for &gt;30 days or cumulative dose ≥5 g in 1 year) We conditionally recommend treating with PTH/PTHrP over anti-resorptives.|Low|6.1b–6.19a|120–141|\n|Oral BP are strongly recommended over no treatment.|Low|6.1b–6.19a|120–141|",
            "risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).  Recommendations for initial treatment (Table 2 3 For adults ≥40 years with very high fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptives (BP or DEN) (PICO 1.13c, 1.14c, 1.15c, 1.18c, 1.19c, 1.20c). Compared to alendronate, teriparatide increased lumbar and hip BMD and decreased vertebral but not nonvertebral fractures at 36 months in GIOP For adults ≥40 years with high or very high fracture risk, we",
            "The relative risk for vertebral fracture was 14 and for hip fractures was 3 with a dose of ≥30 mg per day and ≥ 5 g of cumulative use For adults <40 years receiving one or more courses of high-dose GC therapy (mean dose prednisone equivalent ≥30 mg daily for ≥30 days) or cumulative GC dose ≥5 g over 1 year, we conditionally recommend oral or IV BP, PTH/PTHrP, DEN. We conditionally recommended against RAL/ROM (PICO 6.4a,b-6.24a,b). In this younger population, PTH/ PTHrP and ROM should only be"
        ]
    },
    {
        "pregunta": "4. What are the potential harms associated with certain osteoporosis medications in patients with glucocorticoid-induced osteoporosis?",
        "respuesta": "The provided information does not include specific details about the potential harms associated with certain medications for treating glucocorticoid-induced osteoporosis. Therefore, I am unable to provide a reliable response based on the given data.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      895E00BE431C5D109F968BA8D0506240 10.1002/acr.25240 Submitted for publication December 1, 2022; accepted in revised form July 3, 2023.  INTRODUCTION Glucocorticoids (GCs) remain a common therapeutic modality for patients with a variety of diseases. Prevention of GC-induced bone loss and fractures has been a focus of the American College of Rheumatology (ACR) for many",
            "associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline"
        ]
    },
    {
        "pregunta": "5. What is the recommended treatment approach for patients under 40 years old receiving high-dose glucocorticoid therapy?",
        "respuesta": "The provided information does not include specific details about the recommended treatment approach for patients under 40 years old who are receiving high-dose glucocorticoid therapy. Therefore, I am unable to provide a reliable response based on the given data.",
        "contexto": [
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "to minimize glucocorticoid exposure and toxicity. Overall, there are few clinical situations in which treatment with glucocorticoid monotherapy may be considered (e.g., arthralgias or inability to tolerate other remission maintenance therapies), and close monitoring is needed if this treatment strategy is used. Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and glucocorticoids over azathioprine and glucocorticoids or",
            "associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not",
            "we conditionally recommend the addition of RAAS-I. …We conditionally recommend pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper to a target dose of ≤5mg/day by 6 months. … Who have achieved/sustained a complete renal response after treatment with any (triple or dual) immunosuppressive therapy, we conditionally recommend a total duration of therapy of at least 3-5 years. IN PEOPLE",
            "position statement: For patients with active, severe EGPA, either IV pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed as initial therapy. There are no data to support favoring either IV pulse or highdose oral glucocorticoids over the other option in active, severe EGPA. Choosing an approach should be influenced by individual patient factors. In either instance, glucocorticoids should be combined with a nonglucocorticoid immunosuppressive agent such as cyclophosphamide"
        ]
    },
    {
        "pregunta": "6. How should osteoporosis therapy be managed in patients who can become pregnant and are at moderate or high risk of fracture?",
        "respuesta": "The provided information does not include specific details about the recommended management of osteoporosis therapy for patients who can become pregnant and are at moderate or high risk of fracture. Therefore, I am unable to provide a reliable response based on the given data.",
        "contexto": [
            "risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).  Recommendations for initial treatment (Table 2 3 For adults ≥40 years with very high fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptives (BP or DEN) (PICO 1.13c, 1.14c, 1.15c, 1.18c, 1.19c, 1.20c). Compared to alendronate, teriparatide increased lumbar and hip BMD and decreased vertebral but not nonvertebral fractures at 36 months in GIOP For adults ≥40 years with high or very high fracture risk, we",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "(>0.1 mg/kg/day), BP therapy is warranted. For adults ≥40 years, the panel voted to give clinicians the ability to select an OP therapy based on the patient's specific comorbidities and preferences, BMD values, fracture history, and other characteristics, rather than rank ordering the medication recommendations. Fracture prevention data in GIOP is currently limited to oral BP and PTH. Anabolic agents may be the preferred initial therapy for those at very high risk for fracture based on BMD and",
            "|BP (Alendronate [oral], Risedronate [oral]; Ibandronate [oral/ IV], Zoledronic acid [IV])|We strongly recommend OP treatment for those at moderate, high, or very high risk of fracture. We strongly recommend oral BP over no treatment in high and very high fracture risk due to fracture reduction in GIOP. We conditionally recommend IV BP, ROM, RAL over no treatment in high and very high risk of fracture. In moderate risk, we conditionally recommend BP, DEN, or PTH/PTHrP in no preferred order",
            "risk of osteoporotic fractures in children and youth ages 4 to 17 years (PICO 7.1a-7.5a). For children and youth ages 4 to 17 years with an osteoporotic fracture who are continuing treatment with chronic GC at a dose of ≥0.1 mg/kg/day for >3 months, treating with an oral or IV BP is conditionally recommended over no treatment.  This conditional recommendation to treat with oral or IV BP to prevent recurrent fractures is based on low-certainty evidence. Depending on the specific disease or cause"
        ]
    },
    {
        "pregunta": "7. What treatment options are conditionally recommended for solid organ transplant recipients on chronic glucocorticoid therapy?",
        "respuesta": "The provided information does not include specific details about the treatment options that are conditionally recommended for solid organ transplant recipients who are on chronic glucocorticoid therapy. Therefore, I am unable to provide a reliable response based on the given data.",
        "contexto": [
            "to minimize glucocorticoid exposure and toxicity. Overall, there are few clinical situations in which treatment with glucocorticoid monotherapy may be considered (e.g., arthralgias or inability to tolerate other remission maintenance therapies), and close monitoring is needed if this treatment strategy is used. Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and glucocorticoids over azathioprine and glucocorticoids or",
            "regimen for remission induction. A recent study demonstrated that a reduced-dose glucocorticoid regimen provided a similar benefit compared to a standarddose regimen for the composite outcome of ESRD or death, and was associated with a decreased risk of infection http://onlin e libr ary.wiley.com/doi/10.1002/acr.24634/ abstract Remission induction for active, nonsevere disease Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with",
            "we conditionally recommend the addition of RAAS-I. …We conditionally recommend pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper to a target dose of ≤5mg/day by 6 months. … Who have achieved/sustained a complete renal response after treatment with any (triple or dual) immunosuppressive therapy, we conditionally recommend a total duration of therapy of at least 3-5 years. IN PEOPLE",
            "choice, because it has been found to be efficacious for nonsevere EGPA in a randomized trial Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with methotrexate, azathioprine, or mycophenolate mofetil and glucocorticoids over glucocorticoids alone. Patients should be treated with adjunctive methotrexate, azathioprine, or mycophenolate mofetil rather than glucocorticoids alone in order to minimize glucocorticoid toxicity. One randomized",
            "IV pulse glucocorticoids to high-dose oral glucocorticoids. Higher doses of glucocorticoids (such as pulse glucocorticoids) are generally administered to patients with organ-or life-threatening disease manifestations but may be associated with an increased risk of infection Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend a reduced-dose glucocorticoid regimen over a standard-dose glucocorticoid regimen for remission induction. A recent study demonstrated that"
        ]
    },
    {
        "pregunta": "8. Why is metabolic bone disease expert evaluation recommended for renal transplant recipients on chronic glucocorticoid therapy?",
        "respuesta": "Evaluation by a metabolic bone disease expert is recommended for renal transplant recipients who are on chronic glucocorticoid therapy because there is an increased risk of renal osteodystrophy when the estimated glomerular filtration rate (eGFR) is less than 35 ml/min. This includes conditions such as adynamic bone disease, osteomalacia, osteitis fibrosa cystica, and mixed uremic osteodystrophy. The expert evaluation is conditionally recommended to exclude these conditions and assess for hyperparathyroidism. Once these conditions are excluded, no dose adjustment is needed when prescribing medications such as denosumab, parathyroid hormone (PTH)/PTH-related protein (PTHrP), or romosozumab, but bisphosphonates should be avoided in this group.",
        "contexto": [
            "overall certainty of evidence for treatment in this population is low, and numerous potentially influential individual patient factors need to be weighed when selecting treatment. For adult renal transplant recipients on chronic GC treatment, we conditionally recommend metabolic bone disease expert evaluation for chronic kidney disease-mineral and bone disorder (CKD-MBD). In patients with stage IV and V CKD, renal osteodystrophy, including adynamic bone disease, osteomalacia, osteitis fibrosa",
            "used in patients with an eGFR < 35 ml/min. When eGFR is < 35 ml/min, the risk of renal osteodystrophy, including adynamic bone disease, osteomalacia, osteitis fibrosa cystica and mixed uremic osteodystrophy, is increased. As such, metabolic bone disease expert evaluation for chronic kidney disease-mineral and bone disorder (CKD-MBD) is conditionally recommended to exclude these conditions. Hyperparathyroidism should also be assessed. Once excluded, no dose adjustment is needed when prescribing",
            "transplant and with CKD was addressed in this guideline. When eGFR <35 mL/min, the risk of renal osteodystrophy is significantly increased, including adynamic bone disease, osteomalacia, osteitis fibrosa cystica, and mixed uremic osteodystrophy. As such, MBD expert evaluation for CKD-MBD is conditionally recommended to exclude these conditions. Once excluded, no dose adjustment is needed when prescribing DEN, PTH/PTHrP, or ROM, but BP should be avoided. Use of DEN in this group may lead to",
            "this guideline, we emphasize the importance of prompt kidney biopsy and LN treatment and propose triple therapy as the most desirable therapy for LN, preferring MPAA regimens over CYC regimens. We propose a lower dose glucocorticoid regimen to minimize toxicity, with a prednisone goal of ≤5 mg/day by 6 months of therapy, and a total therapy duration of 3-5 years for those achieving complete renal response. Discussion between clinicians and patients is critical because multiple factors impact",
            "|For adults with solid organ transplants Glomerular filtration rate ≥35 ml/minute, and no evidence of chronic kidney disease-mineral and bone disorder (CKD-MBD) or hyperparathyroidism| | | |\n|We conditionally recommend expert evaluation for CKD-MBD in renal transplant recipients.|Low|5.1-5.26|103-118|\n|We conditionally recommend treatment with oral or IV BP, DEN, PTH/PTHrP, or RAL based on individual patient factors.|Low|5.1-5.26|103-118|"
        ]
    },
    {
        "pregunta": "9. What are the recommended vitamin D options for patients with chronic kidney disease-mineral and bone disorder?",
        "respuesta": "The provided information indicates that for patients with chronic kidney disease-mineral and bone disorder (CKD-MBD) and an estimated glomerular filtration rate (eGFR) ≥30 mL/min, vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol) can be used instead of biologically active forms of vitamin D. However, patients with an eGFR <30 mL/min might require biologically active forms of vitamin D, such as calcitriol, paricalcitol, or doxercalciferol, to maintain a neutral calcium balance.",
        "contexto": [
            "including adynamic bone disease, osteomalacia, osteitis fibrosa cystica, and mixed uremic osteodystrophy, is nearly universal The panel recommended that patients without hyperparathyroidism and eGFR ≥30 mL/min could use vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol) instead of biologically active forms of vitamin D (calcitriol, paricalticol, or doxercalciferol). Patients with GFR <30 mL/min might require biologically active VitD to maintain neutral calcium balance. For children and",
            "used in patients with an eGFR < 35 ml/min. When eGFR is < 35 ml/min, the risk of renal osteodystrophy, including adynamic bone disease, osteomalacia, osteitis fibrosa cystica and mixed uremic osteodystrophy, is increased. As such, metabolic bone disease expert evaluation for chronic kidney disease-mineral and bone disorder (CKD-MBD) is conditionally recommended to exclude these conditions. Hyperparathyroidism should also be assessed. Once excluded, no dose adjustment is needed when prescribing",
            "|---|---|---|---|\n|For adults and children beginning or continuing chronic GC treatment at low, moderate, high, or very high risk of fracture, we conditionally recommend optimizing dietary and supplemental calcium and vitamin D in addition to lifestyle modifications (CAL/VIT D/LM)|Low or Very Low|1.1a,b,c-1.3a,b,c, 2.1-2.3, 7.16-7.26|6-8, 47-48, 63-65, 141-144, 148-151|\n|In adults ≥40 years (All additional recommendations are in addition to CAL/VIT D/LM.)| | | |",
            "overall certainty of evidence for treatment in this population is low, and numerous potentially influential individual patient factors need to be weighed when selecting treatment. For adult renal transplant recipients on chronic GC treatment, we conditionally recommend metabolic bone disease expert evaluation for chronic kidney disease-mineral and bone disorder (CKD-MBD). In patients with stage IV and V CKD, renal osteodystrophy, including adynamic bone disease, osteomalacia, osteitis fibrosa",
            "transplant and with CKD was addressed in this guideline. When eGFR <35 mL/min, the risk of renal osteodystrophy is significantly increased, including adynamic bone disease, osteomalacia, osteitis fibrosa cystica, and mixed uremic osteodystrophy. As such, MBD expert evaluation for CKD-MBD is conditionally recommended to exclude these conditions. Once excluded, no dose adjustment is needed when prescribing DEN, PTH/PTHrP, or ROM, but BP should be avoided. Use of DEN in this group may lead to"
        ]
    },
    {
        "pregunta": "10. In what population is starting osteoporosis therapy conditionally recommended due to the low risk of osteoporotic fractures?",
        "respuesta": "Starting osteoporosis therapy is conditionally recommended against in the population of adults under 40 years with a low risk of osteoporotic fractures due to the low risk of osteoporotic fractures in this age group. The guideline specifically advises against initiating oral or IV bisphosphonates in this population due to their low fracture risk.",
        "contexto": [
            "|We conditionally recommended against starting oral or IV BP due to low risk of OP fractures in this age group.|Very Low|7.5a|144|\n|Children ages 4-17 years with an osteoporotic fracture Who are continuing treatment with GCs at a dose of ≥0.1 mg/kg/day for &gt;3 months (high risk)| | | |\n| We conditionally recommend treating with an oral or IV BP. | Very low | 7.1b-7.2b | 148-153 |</p>",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "risk of osteoporotic fractures in children and youth ages 4 to 17 years (PICO 7.1a-7.5a). For children and youth ages 4 to 17 years with an osteoporotic fracture who are continuing treatment with chronic GC at a dose of ≥0.1 mg/kg/day for >3 months, treating with an oral or IV BP is conditionally recommended over no treatment.  This conditional recommendation to treat with oral or IV BP to prevent recurrent fractures is based on low-certainty evidence. Depending on the specific disease or cause",
            "GC treatment who have had an osteoporotic fracture ≥12 months after starting OP therapy, or who have had a significant loss of BMD (eg, greater than the least significant change per their DXA machine) after 1 to 2 years of OP treatment, we conditionally recommend changing to another class of OP medication over not switching the class of OP medication (PICO 10.1-10.9). If oral BP is the first OP therapy and suboptimal adherence or poor absorption is suspected, based on low certainty evidence, we",
            "| For adults &lt;40 years with MODERATE fracture risk, we conditionally recommended oral or IV BP%, DEN%, or PTH/PTHrP therapy. | Low or Very low | 2.4-2.22, 3.4-3.17 | 65-76, 79-84 |\n| For adults &lt;40 years with MODERATE fracture risk, we conditionally recommended against using ROM due to risk of myocardial infarction, stroke or death. | Very Low | 2.9, 3.9 | 70, 87 |"
        ]
    }
]